Drug Profile
Research programme: influenza vaccine - Akela Pharma
Latest Information Update: 18 Mar 2013
Price :
$50
*
At a glance
- Originator Nventa Biopharmaceuticals Corporation
- Developer Akela Pharma
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 18 Mar 2013 9147415 - Akela Pharma no longer operating, no indication development was even ongoing at the time they went bankrupt as they'd turned to focus on Formulation Technologies, which was more of a CRO
- 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
- 14 Mar 2013 Discontinued - Preclinical for Influenza virus infections in USA (Parenteral)